What Are Mavenclad and Ocrevus?

Mavenclad (cladribine) and Ocrevus (ocrelizumab) are disease-modifying therapies approved for treating relapsing forms of multiple sclerosis. Mavenclad, developed by EMD Serono, is an oral medication taken as tablets during two treatment courses over two years. It works by temporarily reducing specific types of white blood cells (lymphocytes) that contribute to MS inflammation.

Ocrevus, manufactured by Genentech, is an intravenous infusion administered every six months after initial loading doses. It targets CD20-positive B cells, which are involved in the immune system attack on the myelin sheath that protects nerve fibers. Both medications aim to reduce disease activity and progression, but through different mechanisms and administration methods.

Administration and Treatment Schedule

The administration schedule represents one of the most significant differences between these treatments. Mavenclad follows a unique dosing pattern where patients take tablets for 4-5 days during the first week and another 4-5 days during the fifth week of each treatment year. This process is repeated in the second year, and then no additional Mavenclad treatment is needed for years 3 and 4.

Ocrevus requires a different commitment. Treatment begins with two initial infusions of 300 mg given two weeks apart, followed by 600 mg infusions every six months thereafter. Each infusion session typically lasts 2-4 hours and requires monitoring by healthcare professionals. For patients, this means considering both the convenience of oral medication versus the consistent maintenance of regular infusions when choosing between treatments.

Efficacy and Clinical Results

Clinical trials have demonstrated that both medications effectively reduce MS relapses and slow disease progression, though direct head-to-head studies comparing Mavenclad and Ocrevus are limited. In its pivotal CLARITY trial, Mavenclad reduced annual relapse rates by 57.6% compared to placebo and decreased the risk of 3-month confirmed disability progression by 33%.

Ocrevus has shown impressive results in its clinical studies as well. In trials against interferon beta-1a (Rebif), Ocrevus reduced annual relapse rates by approximately 46-47% and showed a 40% reduction in confirmed disability progression. Notably, Ocrevus is also approved for primary progressive MS (PPMS), a form of MS for which treatment options are more limited, while Mavenclad is only approved for relapsing forms of MS.

The decision between these medications often involves considering individual patient factors, disease characteristics, and preference for treatment administration. Your neurologist can provide guidance based on your specific situation and disease activity.

Provider Comparison and Availability

When considering these treatments, it's important to understand their manufacturers and availability. EMD Serono, the biopharmaceutical business of Merck KGaA, produces Mavenclad. The company has established support programs to help patients navigate insurance coverage and financial assistance options.

Ocrevus is manufactured by Genentech, a member of the Roche Group. Genentech also offers patient support services through their Ocrevus Connect program, which provides resources for insurance verification, infusion coordination, and financial assistance.

Both medications require prescription from a neurologist specializing in MS treatment. Availability may vary depending on your location, insurance coverage, and the specific protocols of your healthcare provider. Most MS centers and neurology practices that specialize in MS care can administer both treatments, though the logistics differ due to the contrasting administration methods.

Safety Profiles and Considerations

The safety profiles of these medications differ significantly and may influence treatment decisions. Mavenclad carries a risk of lymphopenia (low lymphocyte counts), which is actually part of its mechanism of action. Other potential side effects include infections, headache, and a small increased risk of certain malignancies. Mavenclad has several contraindications, including pregnancy (effective contraception is required during treatment and for 6 months after), active chronic infections, and immunocompromised states.

Ocrevus has its own safety considerations, including infusion-related reactions that can occur during or within 24 hours of treatment. These reactions are most common with the first infusion and typically decrease with subsequent doses. Other potential side effects include upper respiratory tract infections, lower respiratory tract infections, and a slight increased risk of infections overall. Like Mavenclad, Ocrevus is not recommended during pregnancy.

Both medications require pre-screening tests, including blood tests and screening for infections like hepatitis B. Your healthcare provider at centers like National MS Society affiliated clinics will monitor you closely during treatment to manage potential side effects and ensure safety.

Conclusion

Choosing between Mavenclad and Ocrevus requires careful consideration of several factors, including your lifestyle preferences, comorbidities, family planning, and specific MS characteristics. The convenience of Mavenclad's oral administration and unique dosing schedule (with no treatment required in years 3-4) appeals to many patients who prefer minimal treatment interventions. Conversely, Ocrevus offers consistent, predictable twice-yearly infusions and is suitable for both relapsing MS and primary progressive MS.

Ultimately, the decision should be made through thorough discussion with your neurologist, who can evaluate your specific disease characteristics, previous treatment responses, and individual risk factors. Both medications represent significant advances in MS treatment, offering effective options to reduce disease activity and potentially slow progression. As MS treatment continues to evolve, staying informed about these options through resources like the National MS Society can help you make the most appropriate treatment decision for your circumstances.

Citations

This content was written by AI and reviewed by a human for quality and compliance.